175 related articles for article (PubMed ID: 15752382)
21. Exemestane.
Scott LJ; Wiseman LR
Drugs; 1999 Oct; 58(4):675-80; discussion 681-2. PubMed ID: 10551437
[TBL] [Abstract][Full Text] [Related]
22. Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits.
Beltrame D; di Salle E; Giavini E; Gunnarsson K; Brughera M
Reprod Toxicol; 2001; 15(2):195-213. PubMed ID: 11297878
[TBL] [Abstract][Full Text] [Related]
23. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor].
Tahara M; Nomura S; Hashimoto M
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):345-54. PubMed ID: 14501171
[TBL] [Abstract][Full Text] [Related]
25. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
[TBL] [Abstract][Full Text] [Related]
26. Exemestane in advanced breast cancer.
Buzdar A
Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study.
Noh YH; Ko YJ; Cho SH; Ghim JL; Choe S; Jung JA; Kim UJ; Jin SJ; Park HJ; Song GS; Lim HS; Bae KS
Clin Ther; 2012 Feb; 34(2):305-13. PubMed ID: 22281018
[TBL] [Abstract][Full Text] [Related]
28. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
Dixon JM
Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic study of a novel oral formulation of S-adenosylmethionine (MSI-195) in healthy subjects: dose escalation, food effect and comparison to a commercial nutritional supplement product.
Cameron BR; Ferreira L; MacDonald ID
BMC Pharmacol Toxicol; 2020 Dec; 21(1):88. PubMed ID: 33317621
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Buzdar AU
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):468S-72S. PubMed ID: 12538502
[TBL] [Abstract][Full Text] [Related]
31. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
32. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Jones S; Vogel C; Arkhipov A; Fehrenbacher L; Eisenberg P; Cooper B; Honig S; Polli A; Whaley F; di Salle E; Tiffany J; Consonni A; Miller L
J Clin Oncol; 1999 Nov; 17(11):3418-25. PubMed ID: 10550136
[TBL] [Abstract][Full Text] [Related]
33. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
[TBL] [Abstract][Full Text] [Related]
34. Pharmacology and clinical experience with exemestane.
Lønning PE
Expert Opin Investig Drugs; 2000 Aug; 9(8):1897-905. PubMed ID: 11060785
[TBL] [Abstract][Full Text] [Related]
35. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
37. Exemestane: a novel aromatase inactivator for breast cancer.
Jones SA; Jones SE
Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
[TBL] [Abstract][Full Text] [Related]
38. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
[TBL] [Abstract][Full Text] [Related]
39. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
40. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
